As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.
Discover >Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.
Discover >Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.
Discover >#Health / Well-being #Diagnostics
Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.
BACKGROUND
Enalees was created in December of 2015.
The company joined Genopole and became Genopole-accredited in February 2016. After two years of research, Enalees commercialized its first tests, Epona, for veterinarians working with horses, and a year later it brought the Astéria line to market for veterinarians working with dogs. Enalees also developed a SARS-CoV-2 diagnostic test during the COVID-19 pandemic to detect the causative virus in humans, cats, and the environment.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
The purpose of Enalees’ rapid tests is to diagnose a disease via a portable reader within 40 minutes with no need to send samples to a specialized laboratory.
Also, in 2021, Enalees will begin offering a freeze drying service to numerous businesses thanks to its new lyophilization platform located at Genopole.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
15 staff members
Strengths:
Simple and rapid detection of pathogens in less than 40 minutes on a portable and affordable device. Energetic and innovative team.
In same field
CGenetix, is a medTech start-up developing in vitro medical diagnostic devices for the follow-up of transplant patients.
Discover
SafeInsight seeks to provide a response to the growing concerns of consumers for the composition of the products they buy and accompanies manufacturers aiming to attentively circumscribe the problem of endocrine disruptors.
Discover
